Last Updated : April 18, 2024
Details
FilesGeneric Name:
insulin icodec
Project Status:
Active
Therapeutic Area:
Diabetes mellitus, type 2
Manufacturer:
Novo Nordisk Canada Inc.
Call for patient/clinician input open:
Brand Name:
Awiqli
Project Line:
Reimbursement Review
Project Number:
SR0790-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
The once-weekly treatment of adults with type 2 diabetes mellitus to improve glycemic control.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
The once-weekly treatment of adults with diabetes mellitus to improve
glycemic control.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | September 06, 2023 |
|---|---|
| Call for patient/clinician input closed | October 30, 2023 |
| Clarification: - Patient input submission received from Diabetes Canada | |
| Submission received | October 18, 2023 |
| Submission accepted | - |
| Review initiated | November 02, 2023 |
| Draft CADTH review report(s) provided to sponsor for comment | February 01, 2024 |
| Deadline for sponsors comments | February 12, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | March 14, 2024 |
| Expert committee meeting (initial) | March 27, 2024 |
| Draft recommendation issued to sponsor | April 11, 2024 |
| Draft recommendation posted for stakeholder feedback | April 18, 2024 |
| End of feedback period | May 03, 2024 |
| Final recommendation issued to sponsor and drug plans | - |
Files
Last Updated : April 18, 2024